Amzal, B., Fu, S., Meng, J., Lister, J., & Karcher, H. (2017). Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. Public Library of Science (PLoS).
Chicago Style (17th ed.) CitationAmzal, Billy, Shuai Fu, Jie Meng, Johanna Lister, and Helene Karcher. Cabozantinib Versus Everolimus, Nivolumab, Axitinib, Sorafenib and Best Supportive Care: A Network Meta-analysis of Progression-free Survival and Overall Survival in Second Line Treatment of Advanced Renal Cell Carcinoma. Public Library of Science (PLoS), 2017.
MLA (9th ed.) CitationAmzal, Billy, et al. Cabozantinib Versus Everolimus, Nivolumab, Axitinib, Sorafenib and Best Supportive Care: A Network Meta-analysis of Progression-free Survival and Overall Survival in Second Line Treatment of Advanced Renal Cell Carcinoma. Public Library of Science (PLoS), 2017.